Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1995 1
1996 1
1997 4
1999 8
2000 28
2001 37
2002 44
2003 26
2004 26
2005 33
2006 59
2007 73
2008 56
2009 53
2010 62
2011 56
2012 65
2013 58
2014 62
2015 60
2016 71
2017 97
2018 74
2019 61
2020 76
2021 57
2022 65
2023 57
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

592 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Pioglitazone.
[No authors listed] [No authors listed] 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000126 Free Books & Documents. Review.
No information is available on the clinical use of pioglitazone during breastfeeding. Pioglitazone is over 99% protein bound in plasma, so it is unlikely to pass into breastmilk in clinically important amounts. ...
No information is available on the clinical use of pioglitazone during breastfeeding. Pioglitazone is over 99% protein bound i …
Pioglitazone.
Karásek D. Karásek D. Vnitr Lek. 2020 Spring;66(2):121-125. Vnitr Lek. 2020. PMID: 32942898 Review. English.
Pioglitazone belongs to the drugs primarily reducing insulin resistance. ...The paper provides an overview of cardiovascular clinical trials with pioglitazone, its safety profile and practical recommendations for its administration....
Pioglitazone belongs to the drugs primarily reducing insulin resistance. ...The paper provides an overview of cardiovascular clinical …
Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes.
DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. DeFronzo RA, et al. Diab Vasc Dis Res. 2019 Mar;16(2):133-143. doi: 10.1177/1479164118825376. Epub 2019 Feb 1. Diab Vasc Dis Res. 2019. PMID: 30706731 Free article. Review.
However, there is strong evidence that an older and now generically available medication, the thiazolidinedione, pioglitazone, can retard the atherosclerotic process (PERISCOPE and Chicago) and reduce cardiovascular events in large randomized prospective cardiovascular out …
However, there is strong evidence that an older and now generically available medication, the thiazolidinedione, pioglitazone, can re …
Pioglitazone.
Al-Majed A, Bakheit AH, Abdel Aziz HA, Alharbi H, Al-Jenoobi FI. Al-Majed A, et al. Profiles Drug Subst Excip Relat Methodol. 2016;41:379-438. doi: 10.1016/bs.podrm.2015.11.002. Epub 2016 Feb 2. Profiles Drug Subst Excip Relat Methodol. 2016. PMID: 26940171 Review.
Pioglitazone is a thiazolidinedione antidiabetic with actions similar to those of rosiglitazone. ...Following oral administration, approximately 15-30% of the pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is negligible, and th …
Pioglitazone is a thiazolidinedione antidiabetic with actions similar to those of rosiglitazone. ...Following oral administration, ap …
Pioglitazone.
[No authors listed] [No authors listed] 2018 Jun 6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Jun 6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643649 Free Books & Documents. Review.
Pioglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Pioglitazone has been linked to rare instances of acute liver injury....
Pioglitazone is an insulin sensitizing agent and thiazolidinedione that is indicated for the treatment of type 2 diabetes. Pioglit …
Reassessment of Pioglitazone for Alzheimer's Disease.
Saunders AM, Burns DK, Gottschalk WK. Saunders AM, et al. Front Neurosci. 2021 Jun 16;15:666958. doi: 10.3389/fnins.2021.666958. eCollection 2021. Front Neurosci. 2021. PMID: 34220427 Free PMC article. Review.
This review summarizes key aspects of the biology and genetics of Alzheimer's disease, and we describe how pioglitazone improves many of the patholophysiological determinants of AD. We also summarize the results of pre-clinical experiments, longitudinal observational studi …
This review summarizes key aspects of the biology and genetics of Alzheimer's disease, and we describe how pioglitazone improves many …
Pioglitazone for the treatment of Alzheimer's disease.
Galimberti D, Scarpini E. Galimberti D, et al. Expert Opin Investig Drugs. 2017 Jan;26(1):97-101. doi: 10.1080/13543784.2017.1265504. Epub 2016 Dec 4. Expert Opin Investig Drugs. 2017. PMID: 27885860 Review.
These drugs provide mainly symptomatic short-term benefits without clearly influencing the progression of the disease. Pioglitazone (AD4833) is an insulin sensitizer of the thiazolidinedione class of nuclear Peroxisome-Proliferator Activated Receptor gamma (PPARgamma) agon …
These drugs provide mainly symptomatic short-term benefits without clearly influencing the progression of the disease. Pioglitazone ( …
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis.
Filipova E, Uzunova K, Kalinov K, Vekov T. Filipova E, et al. Diabetes Ther. 2017 Aug;8(4):705-726. doi: 10.1007/s13300-017-0273-4. Epub 2017 Jun 16. Diabetes Ther. 2017. PMID: 28623552 Free PMC article. Review.
People with type 2 diabetes are at increased risk of bladder cancer. Pioglitazone is said to increase it further, although published evidence is mixed. ...The overall RR was 1.13 with 95% CI (0.96-1.33) with low heterogeneity among the studies using RR, suggesting that no …
People with type 2 diabetes are at increased risk of bladder cancer. Pioglitazone is said to increase it further, although published …
Pioglitazone and bladder cancer: FDA's assessment.
Hampp C, Pippins J. Hampp C, et al. Pharmacoepidemiol Drug Saf. 2017 Feb;26(2):117-118. doi: 10.1002/pds.4154. Epub 2017 Jan 9. Pharmacoepidemiol Drug Saf. 2017. PMID: 28067434 Review. No abstract available.
In praise of pioglitazone: An economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome.
Bell DSH, Jerkins T. Bell DSH, et al. Diabetes Obes Metab. 2023 Nov;25(11):3093-3102. doi: 10.1111/dom.15222. Epub 2023 Aug 3. Diabetes Obes Metab. 2023. PMID: 37534526 Review.
Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also by improving beta cell function. ...The manifestations of diseases associated with insulin resistance (non-alcoholic steatohepatitis and polycystic ovary disease) are also improved w …
Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also by improving beta cell function. ...The ma …
592 results